

1. Record Nr.	UNINA9911018763903321
Autore	Deng Wu-Min
Titolo	The Drosophila Model in Cancer : Volume II / / edited by Wu-Min Deng, Cayetano Gonzaléz
Pubbl/distr/stampa	Cham : , : Springer Nature Switzerland : , : Imprint : Springer, , 2025
ISBN	3-031-97035-7
Edizione	[1st ed. 2025.]
Descrizione fisica	1 online resource (492 pages)
Collana	Advances in Experimental Medicine and Biology, , 2214-8019 ; ; 1482
Altri autori (Persone)	GonzalézCayetano
Disciplina	571.978 616.994
Soggetti	Cancer Cancer - Animal models Cancer - Genetic aspects Cancer Biology Cancer Models Cancer Genetics and Genomics Cancers
Lingua di pubblicazione	Inglese
Formato	Materiale a stampa
Livello bibliografico	Monografia
Nota di contenuto	Chapter 1. Unveiling the Tumor Suppressors: Insights from Drosophila -- Chapter 2. Notch signaling in Drosophila tumor models -- Chapter 3. Non-autonomous Regulation of Tumor Growth -- Chapter 4. Transcriptional Regulation of Lipid Metabolism by Wnt Signaling and Hox Protein Cues. - Chapter 5. The power of Drosophila in Modeling Cancer Cachexia -- Chapter 6. Drosophila Intestine as a Model to Study Tumors -- Chapter 7. Host-microbe Interactions in Drosophila Cancer -- Chapter 8. Drosophila as a Model for Metastasis -- Chapter 9. Epigenetic regulation in Drosophila Tumor Models -- Chapter 10. From the Making of a neural lineage to the Making of a Tumor: Lessons from the "simple" Drosophila Brain -- Chapter 11. Drosophila Melanogaster as a Model System for Human Glioblastoma -- Chapter 12. Translationally Controlled Tumor Protein (Tctp) and Growth Regulation in the Drosophila model -- Chapter 13. Modelling Cancer in Drosophila: Exploration to Personalised Medicine -- Chapter 14. SVC112; from hummingbirds to Head and Neck Cancer.

Sommario/riassunto

This volume brings together a series of review articles that highlight new advances in using the fruit fly, *Drosophila melanogaster*, to study a wide range of cancer-related topics. Building on the foundation of Volume I, the articles demonstrate how research in *Drosophila* continues to uncover important developmental, cellular, and molecular mechanisms underlying tumor growth, progression, and systemic interactions. Readers will appreciate how the fly's simple genetics and powerful experimental tools make it a flexible and effective model for studying cancer. *Drosophila* offers unique opportunities to answer key questions about how uncontrolled cell proliferation begins and progresses into cancer—questions that can be very difficult to explore in other systems. This book is a valuable resource for researchers interested in using the *Drosophila* model to better understand cancer biology and to help find new strategies to combat this disease.

2. Record Nr.**Titolo**

UNINA9910967295803321

Initial national priorities for comparative effectiveness research / / Committee on Comparative Effectiveness Research Prioritization, Board on Health Care Services, Institute of Medicine of the National Academies

Pubbl/distr/stampa

Washington, D.C., : National Academies Press, c2009

ISBN9786612412547
9781282412545
128241254X
9780309138376
030913837X**Edizione**

[1st ed.]

Descrizione fisica

1 online resource (252 p.)

Disciplina

610.72073

SoggettiMedicine - Research - United States
Medical policy - United States**Lingua di pubblicazione**

Inglese

Formato

Materiale a stampa

Livello bibliografico

Monografia

Note generali

Description based upon print version of record.

Nota di bibliografia

Includes bibliographical references.

Nota di contenuto

""Reviewers""; ""Foreword""; ""Preface""; ""Acknowledgments"";

""Contents""; ""Boxes, Figures, and Tables""; ""Summary""; ""1 Introduction""; ""2 What Is Comparative Effectiveness Research?""; ""3 Obtaining Input to Identify National Priorities for Comparative Effectiveness Research""; ""4 The Criteria and Process for Setting Priorities""; ""5 Priorities for Study""; ""6 Essential Priorities for a Robust CER Enterprise""; ""Appendix A: Public Meeting AgendaMarch 20, 2009""; ""Appendix B: Stakeholder Questionnaire""; ""Appendix C: Data Tables: Burden of Disease and Variation of Care""; ""Appendix D: Cardiovascular and Peripheral Vascular Cover Sheet""; ""Appendix E: Definitions of Medical Terminology in CER Priority List""; ""Appendix F: Committee Biographies""

Sommario/riassunto

Clinical research presents health care providers with information on the natural history and clinical presentations of disease as well as diagnostic and treatment options. In today's healthcare system, patients, physicians, clinicians and family caregivers often lack the sufficient scientific data and evidence they need to determine the best course of treatment for the patients' medical conditions. Initial National Priorities for Comparative Effectiveness Research (CER) is designed to fill this knowledge gap by assisting patients and healthcare providers across diverse settings in making more informed decisions. In this 2009 report, the Institute of Medicine's Committee on Comparative Effectiveness Research Prioritization establishes a working definition of CER, develops a priority list of research topics, and identifies the necessary requirements to support a robust and sustainable CER enterprise. As part of the 2009 American Recovery and Reinvestment Act, Congress appropriated \$1.1 billion in federal support of CER, reflecting legislators' belief that better decisions about the use of health care could improve the public's health and reduce the cost of care. The Committee on Comparative Effectiveness Research Prioritization was successful in preparing a list 100 top priority CER topics and 10 recommendations for best practices in the field.
